Inhibikase Therapeutics (IKT) Income towards Parent Company (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Income towards Parent Company of -$17.8 million for Q1 2026, down 22.22% year-over-year from -$22.9 million in Q1 2025, and down 29.52% quarter-over-quarter from -$13.8 million in Q4 2025.
Inhibikase Therapeutics (IKT) Income towards Parent Company (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Income towards Parent Company data on file, last reported at -$17.8 million in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at -$17.8 million, down 22.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$55.2 million (down 43.78% YoY), and the FY2025 annual result was -$52.0 million, down 81.8% from the prior year.
- Income towards Parent Company retreated to -$17.8 million in Q1 2026 per IKT's latest filing, from -$13.8 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$4.3 million in Q4 2022 and troughed at -$17.8 million in Q1 2026.
- A 5-year average of -$8.0 million and a median of -$5.1 million in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company gained 18.57% in 2024, then slumped 205.25% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at -$4.3 million in 2022, then dropped by 1.58% to -$4.4 million in 2023, then sank by 193.6% to -$12.9 million in 2024, then fell by 6.55% to -$13.8 million in 2025, then declined by 29.52% to -$17.8 million in 2026.
- Business Quant data shows IKT's Income towards Parent Company at -$17.8 million in Q1 2026, -$13.8 million in Q4 2025, and -$12.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.84 Mn |
| Dec 31, 2025 | -13.78 Mn |
| Sep 30, 2025 | -12.77 Mn |
| Jun 30, 2025 | -10.83 Mn |
| Mar 31, 2025 | -14.60 Mn |
| Dec 31, 2024 | -12.93 Mn |
| Sep 30, 2024 | -5.83 Mn |
| Jun 30, 2024 | -5.05 Mn |
| Mar 31, 2024 | -4.78 Mn |
| Dec 31, 2023 | -4.40 Mn |
| Sep 30, 2023 | -4.77 Mn |
| Jun 30, 2023 | -6.20 Mn |
| Mar 31, 2023 | -4.71 Mn |
| Dec 31, 2022 | -4.33 Mn |
| Sep 30, 2022 | -4.49 Mn |
| Jun 30, 2022 | -4.64 Mn |
| Mar 31, 2022 | -4.64 Mn |
| Dec 31, 2021 | -5.04 Mn |
| Sep 30, 2021 | -4.47 Mn |
| Jun 30, 2021 | -2.64 Mn |